News | November 09, 2025
Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
Subscribe To Our Newsletter & Stay Updated
